Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Young Soon Na"'
Publikováno v:
Biochemical and Biophysical Research Communications. 529:699-706
Gastrointestinal stromal tumor (GIST) is the most common sarcoma in the gastrointestinal (GI) tract. Approximately 85% of the GIST is associated with a c-KIT mutation. A few GISTs show mutations in the gene encoding platelet-derived growth factor rec
Autor:
Baek-Yeol Ryoo, Min-Hee Ryu, Ju-Kyung Lee, Young-Soon Na, Youngsoo Park, Yangsoon Park, Yoon-Koo Kang, Chae-Won Lee, Seyoung Seo
Publikováno v:
Chinese Journal of Cancer Research
Objective To investigate the clinical significance of MET gene amplification in patients with gastric cancer in the palliative setting. Methods MET amplification was assessed using fluorescence in situ hybridization (FISH) in 50 patients and quantita
Autor:
Hyungeun Lee, Hyung-Don Kim, Yoon-Koo Kang, Hyung Geun Song, Sangsoon Yoon, Min-Hee Ryu, Meesun Moon, Young-Soon Na
Publikováno v:
Chinese Journal of Cancer Research
Objective We aimed to investigate the prognostic value of neutrophil-to-lymphocyte ratio (NLR) and myeloid-derived suppressor cells (MDSCs) in gastric cancer patients treated with second-line ramucirumab plus paclitaxel. Methods A total of 116 patien
Autor:
Yangsoon Park, Jungeun Ma, Yoon-Koo Kang, Young Soo Park, Young Soon Na, Jungmin Park, Chae-Won Lee, Min Hee Ryu, Ju Kyung Lee
Publikováno v:
Scientific Reports
Scientific Reports, Vol 10, Iss 1, Pp 1-8 (2020)
Scientific Reports, Vol 10, Iss 1, Pp 1-8 (2020)
Patient-derived xenografts (PDXs) can represent the heterogeneity and histological characteristics of tumors and are thus useful for testing the efficacy of anti-cancer drugs; however, PDXs are difficult to generate, especially for gastrointestinal s
Autor:
Min-Hee Ryu, Ju-Kyung Lee, Sook Ryun Park, Young-Soon Na, Chae-Won Lee, Yoon-Koo Kang, Seyoung Seo, Baek-Yeol Ryoo, Young Soo Park, Seong Joon Park
Publikováno v:
Oncotarget
// Seyoung Seo 1,* , Seong Joon Park 1,* , Min-Hee Ryu 1,* , Sook Ryun Park 1 , Baek-Yeol Ryoo 1 , Young Soo Park 2 , Young-Soon Na 3 , Chae-Won Lee 3 , Ju-Kyung Lee 3 and Yoon-Koo Kang 1 1 Department of Oncology, Asan Medical Center, University of U
Autor:
Ju Kyung Lee, Min Hee Ryu, Changhoon Yoo, Jung Min Park, Young Soon Na, Sun Young Lee, Chae-Won Lee, Young Kyoung Shin, Yoon-Koo Kang, Ja-Lok Ku, Sung-Min Ahn
Publikováno v:
Oncotarget
// Young-Soon Na 1, * , Min-Hee Ryu 2, * , Changhoon Yoo 2 , Ju-Kyung Lee 1 , Jung Min Park 1 , Chae-Won Lee 1 , Sun Young Lee 1 , Young-Kyoung Shin 3 , Ja-Lok Ku 3 , Sung-Min Ahn 4 and Yoon-Koo Kang 2 1 Asan Institute for Life Science, Asan Medical
Publikováno v:
Annals of Oncology. 25:2272-2277
Background An exploratory translational analysis was conducted as part of a phase II study of dovitinib to assess the relevance of soluble serum proteins and circulating tumor (ct) DNA (ctDNA) as biomarkers in patients with tyrosine kinase inhibitor
Autor:
Sung-Moo Kim, Shu Yuan Chiang, Junho Song, Dongwoo Nam, Kwang Seok Ahn, Bum Sang Shim, Won-Seok Chung, Hyeung-Jin Jang, Young-Soon Na, Ji-Sung Kim, Sunghoon Kim, Sang Hoon Jung
Publikováno v:
Journal of Medicinal Food. 17:365-373
The identification of the active compounds of herbal medicines and the molecular targets of those compounds is an attractive therapeutic objective. Reynoutria elliptica has been used for the treatment of various inflammatory diseases as a Korean folk
Autor:
Kyoungmin Lee, Kazuko Sakai, Min-Hee Ryu, Jae-Joon Kim, Young Soo Park, Young-Soon Na, Jungeun Ma, Hana Na, Kazuto Nishio, Yoon-Koo Kang
Publikováno v:
Cancer Research. 79:3986-3986
Introduction: With the recent introduction of human epidermal growth factor receptor 2 (HER2) targeted therapies for patients with advanced gastric cancer (AGC), determining HER2 status is essential to select the patients who may benefit from this tr
Autor:
Min-Hee Ryu, Young-Soon Na, Young Soo Park, JW Lee, Chae-Won Lee, Jungmin Park, Yoon-Koo Kang, Jungeun Ma, Yangsoon Park
Publikováno v:
Cancer Research. 79:1058-1058
BACKGROUND: The gastrointestinal stromal tumor (GIST) has activating mutations in either KIT or platelet-derived growth factor receptor alpha (PDGFRa) gene, and tyrosine kinase inhibitors (TKIs) such as imatinib, sunitinib and regorafenib remain the